Ideas

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA LINC00319 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 22/March/2019, 8.23 am
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA LINC00319 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 22/March/2019, 8.23 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA H19 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 22/March/2019, 8.14 am
Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA H19 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 22/March/2019, 8.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA PVT1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 22/March/2019, 8.05 am
Ribonucleic acid-based therapy for glaucoma:  LncRNA PVT1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 22/March/2019, 8.05 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Hydrogen gas-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Subcutaneous injection or inhalation of hydrogen gas decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 21/March/2019, 7.45 pm
Hydrogen gas-based therapy for attenuating pathogenesis-associated with Myocardial infarction: Subcutaneous injection or inhalation of hydrogen gas decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 21/March/2019, 7.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston,…

read more

Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MEG3 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 21/March/2019, 8.49  am
Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MEG3 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 21/March/2019, 8.49  am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Molecular therapy for diabetes (TIDM): Nifedipine (trade names: Adalat and others), a drug used in the treatment of angina, and high blood pressure, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 21/March/2019, 8.40 am
Molecular therapy for diabetes (TIDM): Nifedipine (trade names: Adalat and others), a drug used in the treatment of angina, and high blood pressure, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 21/March/2019, 8.40 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more
Start Typing